You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDimenhydrinate
Accession NumberDB00985  (APRD00924)
TypeSmall Molecule
GroupsApproved
Description

Dimenhydrinate (Dramamine, Gravol and Vertirosan) is an over-the-counter drug used to prevent motion sickness. It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-antagonist, but also possesses an antimuscarinic effect.

Structure
Thumb
Synonyms
(O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhidrinato
Dimenhydrinatum
Diphenhydramine 8-chlorotheophyllinate
Diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Diphenhydrinate
N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alveda Dimenhydrinate Injection USP 50 mg/mlsolution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2016-01-28Not applicableCanada
Dimenhydrinate Inj 10mgliquid10 mgintravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Inj 10mg/mlliquid10 mgintravenousAstra Pharma Inc.1986-12-311999-07-29Canada
Dimenhydrinate Inj 50mg USPliquid50 mgintramuscular; intravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Injection 50mg/mlsolution50 mgintramuscular; intravenousAstrazeneca Canada Inc1986-12-312005-05-31Canada
Dimenhydrinate Injection USP 250mg/5ml (50mg/ml)solution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2008-06-26Not applicableCanada
Dimenhydrinate Injection USP With Preservativesolution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2016-01-28Not applicableCanada
Dimenhydrinate Injection, USPsolution50 mgintramuscular; intravenousMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada
Gravol Imsolution50 mgintramuscularChurch & Dwight Canada Corp1953-12-31Not applicableCanada
Gravol IV Ampoulessolution10 mgintravenousChurch & Dwight Canada Corp1953-12-312008-07-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimenhydrinateinjection, solution50 mg/mLintramuscular; intravenousAPP Pharmaceuticals, LLC2004-11-29Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Airmit Acetablet25 mg/1oralSato Pharmaceutical Co., Ltd.2005-03-11Not applicableUs
Anti-nauseanttablet50 mgoralPharmascience IncNot applicableNot applicableCanada
Anti-nauseanttablet50 mgoralPharmascience Inc2002-08-23Not applicableCanada
Anti-nauseanttablet50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Anti-nauseanttablet50 mgoralVita Health Products Inc2000-05-01Not applicableCanada
Anti-nauseanttablet50 mgoralApotex Inc2013-07-02Not applicableCanada
Anti-nauseant Tablettablet50 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1998-05-262008-08-07Canada
Apo Dimenhydrinate Tab 50mgtablet50 mgoralApotex Inc1977-12-31Not applicableCanada
Children's Motion Sickness Liqliquid15 mgoralTanta Pharmaceuticals Inc1996-12-31Not applicableCanada
Dimenhydrinatetablet, film coated50 mg/1oralTime Cap Labs, Inc2011-01-28Not applicableUs
Dimenhydrinatetablet50 mg/1oralContract Pharmacal Corp2001-01-12Not applicableUs
Dimenhydrinatetablet50 mg/1oralCarilion Materials Management2004-03-01Not applicableUs
Dimenhydrinatetablet50 mg/1oralA S Medication Solutions Llc2004-03-01Not applicableUs
Dimenhydrinatetablet50 mg/1oralQualitest Pharmaceuticals2015-06-05Not applicableUs
Dimenhydrinatetablet50 mg/1oralQualitest Pharmaceuticals2004-03-01Not applicableUs
Dimenhydrinate 50mgtablet50 mgoralPro Doc Limitee1963-12-312010-07-13Canada
Dimenhydrinate Capsulescapsule50 mgoralApotex Inc2014-07-24Not applicableCanada
Dimenhydrinate Liquid for Childrenliquid15 mgoralSupplements Aromatik Inc.Not applicableNot applicableCanada
Dimenhydrinate Tab 50mgtablet50 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Dimenhydrinate Tab 50mg USPtablet50 mgoralPharmetics (2011) Inc1995-12-312000-08-21Canada
Dimenhydrinate Tablet USP 50mgtablet50 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Dimenhydrinate Tabletstablet50 mgoralTanta Pharmaceuticals Inc2001-11-06Not applicableCanada
Dinatetablet50.0 mgoralJaapharm Canada Inc.1999-05-20Not applicableCanada
Dramaminetablet, chewable50 mg/1oralLil' Drug Store Products, Inc.2010-05-10Not applicableUs
Dramamine for Kidstablet, chewable25 mg/1oralMedtech Products Inc.2012-02-15Not applicableUs
Dramamine Orangetablet, chewable50 mg/1oralMedtech Products Inc.2012-01-15Not applicableUs
Dramamine Original Formulatablet50 mg/1oralMedtech Products Inc.2012-01-15Not applicableUs
Driminatetablet50 mg/1oralAvera Mc Kennan Hospital2015-04-27Not applicableUs
Driminatetablet50 mg/1oralMajor Pharmaceuticals1992-12-01Not applicableUs
Gravol Capsules Long Acting 75mgcapsule (sustained-release)75 mgoralChurch & Dwight Canada Corp1956-12-312005-08-01Canada
Gravol Comfort Shaped Suppositoriessuppository100 mgrectalChurch & Dwight Canada Corp1951-12-31Not applicableCanada
Gravol Easy To Swallow Tabletstablet50 mgoralChurch & Dwight Canada Corp1980-12-31Not applicableCanada
Gravol Filmkote Tab 15mgtablet15 mgoralChurch & Dwight Canada Corp1980-12-312014-06-26Canada
Gravol Immediate Release & Long Acting Capletstablet (combined release)100 mgoralChurch & Dwight Canada Corp2005-02-10Not applicableCanada
Gravol Junior Suppositories 50mgsuppository50 mgrectalChurch & Dwight Canada Corp1951-12-312008-07-30Canada
Gravol Kids Comfort Shaped Suppositoriessuppository25 mgrectalChurch & Dwight Canada Corp1989-12-31Not applicableCanada
Gravol Kids Liquidsyrup15 mgoralChurch & Dwight Canada Corp1951-12-31Not applicableCanada
Gravol Kids Quick Dissolve Chewabletablet (chewable)15 mgoralChurch & Dwight Canada Corp2012-11-14Not applicableCanada
Gravol Long Acting Caplettablet (extended-release)75 mgoralChurch & Dwight Canada Corp2002-09-232005-08-01Canada
Gravol Quick Dissolve Chewabletablet (chewable)50 mgoralChurch & Dwight Canada Corp2012-11-14Not applicableCanada
Gravol Tab 25mgtablet25 mgoralChurch & Dwight Canada Corp1994-12-312008-07-30Canada
Gravol Tastefree Liquid Gel Capsulescapsule50 mgoralChurch & Dwight Canada Corp2002-09-23Not applicableCanada
Jamp-dimenhydrinate 50 Mg Tabletstablet50 mgoralJamp Pharma Corporation2003-07-31Not applicableCanada
Motion Sicknesstablet50 mg/1oralGREAT LAKES WHOLESALE, MARKETING, & SALES, INC.1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralL&R Distributors, Inc.1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralWOONSOCKET PRESCRIPTION CENTER,INCORPORATED1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralTarget Corporation1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralFreds Inc2010-07-08Not applicableUs
Motion Sicknesstablet50 mg/1oralMEIJER, INC.2014-03-28Not applicableUs
Motion Sicknesstablet50 mg/1oralHarmon Store Inc.1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralChain Drug Consortium, LLC2014-01-31Not applicableUs
Motion Sicknesstablet50 mg/1oralTOP CARE (Topco Associates LLC)2013-05-31Not applicableUs
Motion Sickness Children's Chewable Tabletstablet (chewable)15 mgoralTanta Pharmaceuticals IncNot applicableNot applicableCanada
Motion Sickness Original Formulatablet50 mg/1oralCVS Pharmacy2014-04-15Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralMc Kesson (Sunmark)2011-06-13Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralNational Distribution Network (Smart Choice)2014-06-30Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralGood Sense (Geiss, Destin & Dunn, Inc.)2010-08-10Not applicableUs
Motion Sickness Relieftablet50 mg/1oralRite Aid1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralHarmon Stores2015-03-31Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWal Mart Stores Inc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralChain Drug Marketing Association Inc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWestern Family Foods, Inc.2010-07-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralAmerisource Bergen Drug Corporation (Good Neighbor Pharmacy) 243852010-07-09Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWin Co Foods, Llc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralBetter Living Brands, Llc1992-12-01Not applicableUs
Motion Sickness Relief Liquid Gelscapsule50 mgoralAccucaps Industries LimitedNot applicableNot applicableCanada
Motion Sickness Relief Original Formulatablet50 mg/1oralCare One (American Sales Company)2010-07-15Not applicableUs
Motion Sickness Tab 50mgtablet50 mgoralDrug Trading Company Ltd.1977-12-311996-09-17Canada
Motion Sickness Tablets 50mgtablet50 mgoralD.C. Labs Limited1995-12-312005-07-19Canada
Nauseatoltablet (chewable)15 mgoralSandoz Canada Incorporated1994-12-31Not applicableCanada
Nauseatoltablet (chewable)50 mgoralSandoz Canada Incorporated1979-12-31Not applicableCanada
Nausex Tab 50mgtablet50 mgoralNobel Pharm Enr.1981-12-311998-08-14Canada
Orb-dimenhydrinate Tablets USPtablet50 mgoralOrbus Pharma IncNot applicableNot applicableCanada
Original Formula Motion Sickness Relieftablet50 mg/1oralCardinal Health (Leader) 372052012-06-26Not applicableUs
Original Formula Motion Sickness Relieftablet50 mg/1oralMc Kesson (Health Mart)2012-06-26Not applicableUs
Pac-kit Motion Sicknesstablet, coated50 mg/1oralAcme United Corporation2013-10-21Not applicableUs
Physicianscare Dimenhydrinate Motion Sickness Relieftablet, coated50 mg/1oralAcme United Corporation2013-10-05Not applicableUs
PMS-dimenhydrinate Syr 3mg/mlsyrup3 mgoralPharmascience Inc1996-08-23Not applicableCanada
PMS-dimenhydrinate Tab 50mgtablet50 mgoralPharmascience Inc1984-12-31Not applicableCanada
Riva-dimenhydrinate Tabletstablet50 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Dimenhydrinatesuppository50 mgrectalSandoz Canada Incorporated1974-12-31Not applicableCanada
Sandoz Dimenhydrinatesuppository100 mgrectalSandoz Canada Incorporated1974-12-31Not applicableCanada
Sicknoltablet50 mgoralBromed Pharmaceuticals Inc.Not applicableNot applicableCanada
Teva-dimenatetablet50 mgoralTeva Canada Limited1967-12-31Not applicableCanada
Travamine Sup 50mgsuppository50 mgrectalIcn Canada Ltd.1979-12-312005-05-04Canada
Travamine Tab 50mgtablet50 mgoralIcn Canada Ltd.1962-12-312005-05-04Canada
Travel Easetablet50 mg/1oralBest Choice (Valu Merchandisers Company)2010-08-10Not applicableUs
Travel Sicknesstablet50 mg/1oralQUALITY CHOICE (Chain Drug Marketing Association)2010-07-14Not applicableUs
Travel Tabstablet50 mgoralTanta Pharmaceuticals Inc2010-01-07Not applicableCanada
Travel Tabs 50 mgtablet50 mgoralVita Health Products Inc1984-12-31Not applicableCanada
Travelmate Tab 50mgtablet50 mgoralShoppers Drug Mart Inc.1979-12-311998-08-14Canada
Travelmate-dimenhydrinate Tablets 50mgtablet50 mgoralKsl Pharmaceuticals1992-12-311997-08-08Canada
Traveltabs 50mgtablet50 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1972-12-312002-07-31Canada
Wal-dramtablet50 mg/1oralWALGREEN CO.1992-12-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
GravolChurch & Dwight
VertirosanAstellas
Vomex AAstellas
XamaminaAdilna
Brand mixtures
NameLabellerIngredients
Gravergol CapsulesCan Med Pharma Inc.
SaltsNot Available
Categories
UNIIJB937PER5C
CAS number523-87-5
WeightAverage: 469.964
Monoisotopic: 469.188067494
Chemical FormulaC24H28ClN5O3
InChI KeyInChIKey=DKHVTDUUNTVKOW-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)
IUPAC Name
8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide; [2-(diphenylmethoxy)ethyl]dimethylazanium
SMILES
CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Benzylether
  • Pyrimidone
  • Pyrimidine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Vinylogous amide
  • Quaternary ammonium salt
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Organic zwitterion
  • Aromatic homomonocyclic compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkNot Available
External Descriptors
Pharmacology
IndicationUsed for treating vertigo, motion sickness, and nausea associated with pregnancy.
PharmacodynamicsDimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.
Mechanism of actionThe mechanism by which some antihistamines exert their antiemetic, anti–motion sickness, and antivertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.
Related Articles
AbsorptionWell absorbed after oral administration.
Volume of distributionNot Available
Protein binding98 to 99%.
Metabolism

Hepatic (cytochrome P-450 system).

Route of eliminationNot Available
Half life1 to 4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.8551
Caco-2 permeable+0.5198
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor INon-inhibitor0.6923
P-glycoprotein inhibitor IIInhibitor0.6502
Renal organic cation transporterNon-inhibitor0.6507
CYP450 2C9 substrateNon-substrate0.7536
CYP450 2D6 substrateNon-substrate0.8181
CYP450 3A4 substrateSubstrate0.7086
CYP450 1A2 substrateInhibitor0.5287
CYP450 2C9 inhibitorNon-inhibitor0.6308
CYP450 2D6 inhibitorNon-inhibitor0.8589
CYP450 2C19 inhibitorNon-inhibitor0.5817
CYP450 3A4 inhibitorNon-inhibitor0.9028
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5738
Ames testNon AMES toxic0.5629
CarcinogenicityNon-carcinogens0.7548
BiodegradationNot ready biodegradable0.8211
Rat acute toxicity2.4087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5364
hERG inhibition (predictor II)Inhibitor0.5405
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alra laboratories inc
  • Heather drug co inc
  • Nexgen pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg/1
Liquidoral15 mg
Injection, solutionintramuscular; intravenous50 mg/mL
Tablet, film coatedoral50 mg/1
Liquidintravenous10 mg
Liquidintramuscular; intravenous50 mg
Solutionintramuscular; intravenous50 mg
Tabletoral50 mg
Tabletoral50.0 mg
Tablet, chewableoral25 mg/1
Tablet, chewableoral50 mg/1
Capsule
Capsule (sustained-release)oral75 mg
Suppositoryrectal100 mg
Tabletoral15 mg
Solutionintramuscular50 mg
Tablet (combined release)oral100 mg
Solutionintravenous10 mg
Suppositoryrectal25 mg
Syruporal15 mg
Tablet (extended-release)oral75 mg
Tabletoral25 mg
Capsuleoral50 mg
Tablet (chewable)oral15 mg
Tablet (chewable)oral50 mg
Tablet, coatedoral50 mg/1
Syruporal3 mg
Suppositoryrectal50 mg
Tabletoral50 mg/1
Prices
Unit descriptionCostUnit
Dimenhydrinate 50 mg/ml vial5.7USD ml
Dimenhydrinate I.M. 50 mg/ml1.17USD ml
Meclizine 12.5 mg tablet0.62USD tablet
Dramamine less drowsy tablet0.42USD tablet
Dimenhydrinate I.V. 10 mg/ml0.32USD ml
Dramamine 50 mg tablet0.28USD tablet
Novamine 15% iv solution0.09USD ml
Dimenhydrinate 100% powder0.07USD g
Driminate 50 mg tablet0.05USD tablet
Dimenhydrinate 50 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point102.5-104Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
water solubility3000 mg/LMERCK INDEX (1996); approx.
logP-0.39Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00125 mg/mLALOGPS
logP2.67ALOGPS
logP3.65ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area13.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.94 m3·mol-1ChemAxon
Polarizability30.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co.
Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.

General References
  1. Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T: Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl. 1993;501:10-5. [PubMed:8447218 ]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984 ]
  3. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 56:22.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72 KB)
Interactions
Drug Interactions
Drug
AclidiniumAclidinium may increase the anticholinergic activities of Dimenhydrinate.
AmphetamineAmphetamine may decrease the sedative activities of Dimenhydrinate.
AzelastineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dimenhydrinate.
Benzylpenicilloyl PolylysineDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dimenhydrinate.
Botulinum Toxin Type ADimenhydrinate may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDimenhydrinate may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
BuprenorphineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
CathinoneCathinone may decrease the sedative activities of Dimenhydrinate.
Cimetropium BromideDimenhydrinate may increase the anticholinergic activities of Cimetropium Bromide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
EluxadolineDimenhydrinate may increase the activities of Eluxadoline.
EthanolDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Glucagon recombinant.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.
HydrocodoneDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Dimenhydrinate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dimenhydrinate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
MethotrimeprazineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosineDimenhydrinate may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Dimenhydrinate.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
MirabegronThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mirabegron.
MirtazapineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MorphineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
OrphenadrineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
Potassium ChlorideDimenhydrinate may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleDimenhydrinate may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Dimenhydrinate.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dimenhydrinate.
RamosetronDimenhydrinate may increase the activities of Ramosetron.
RopiniroleDimenhydrinate may increase the sedative activities of Ropinirole.
RotigotineDimenhydrinate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dimenhydrinate.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Dimenhydrinate.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dimenhydrinate.
SuvorexantDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Dimenhydrinate can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
ThalidomideDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TiotropiumDimenhydrinate may increase the anticholinergic activities of Tiotropium.
TopiramateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Topiramate.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dimenhydrinate.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Dimenhydrinate.
ZolpidemDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 14, 2014 14:37